Literature DB >> 8443122

Expression of PILOT, a putative transcription factor, requires two signals and is cyclosporin A sensitive in T cells.

H W Mages1, T Stamminger, O Rilke, R Bravo, R A Kroczek.   

Abstract

Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA). We have identified a putative transcription factor, designated PILOT, with an identical dual signal requirement for expression. Induction of the PILOT gene is detectable in human T cells 20 min following activation in the presence of cycloheximide and is fully suppressed by CyA. The PILOT protein has a calculated M(r) of 42.6 kDa and contains three zinc fingers of the C2H2-type at the carboxyl-terminus which are highly homologous to the zinc finger regions of the transcription factors EGR1, EGR2, and pAT 133. In contrast to T cells, in fibroblasts PILOT gene expression requires only one signal (PMA) and is not affected by CyA. This observation directly demonstrates the existence of a Ca2+ signal-dependent regulatory element obligatory for expression of some genes in T cells but not in fibroblasts. This differential expression model will be valuable in the dissection of the dual signal pathway in T cells and the effects of CyA upon it.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443122     DOI: 10.1093/intimm/5.1.63

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

1.  Rational primer design greatly improves differential display-PCR (DD-PCR).

Authors:  D Graf; A G Fisher; M Merkenschlager
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

2.  Induction of the early growth response (Egr) family of transcription factors during thymic selection.

Authors:  H Shao; D H Kono; L Y Chen; E M Rubin; J Kaye
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

3.  Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.

Authors:  Jun-ichi Suehiro; Takao Hamakubo; Tatsuhiko Kodama; William C Aird; Takashi Minami
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

4.  Early growth response proteins (EGR) and nuclear factors of activated T cells (NFAT) form heterodimers and regulate proinflammatory cytokine gene expression.

Authors:  Eva L Decker; Nina Nehmann; Eva Kampen; Hermann Eibel; Peter F Zipfel; Christine Skerka
Journal:  Nucleic Acids Res       Date:  2003-02-01       Impact factor: 16.971

5.  Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fibroblasts provides a molecular model for the lymphoid cell-specific effect of cyclosporin A.

Authors:  H W Mages; R Baag; B Steiner; R A Kroczek
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

6.  Early growth response protein-1 (Egr-1) is preferentially expressed in T helper type 2 (Th2) cells and is involved in acute transcription of the Th2 cytokine interleukin-4.

Authors:  Michael Lohoff; Marco Giaisi; Rebecca Köhler; Bärbel Casper; Peter H Krammer; Min Li-Weber
Journal:  J Biol Chem       Date:  2009-11-13       Impact factor: 5.157

7.  Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression.

Authors:  P R Mittelstadt; J D Ashwell
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

Review 8.  Integration of G-protein coupled receptor signaling pathways for activation of a transcription factor (EGR-3).

Authors:  Xuehai Tan; Pam Sanders; Jack Bolado; Mike Whitney
Journal:  Genomics Proteomics Bioinformatics       Date:  2003-08       Impact factor: 7.691

9.  Egr3 induces a Th17 response by promoting the development of γδ T cells.

Authors:  Rose M Parkinson; Samuel L Collins; Maureen R Horton; Jonathan D Powell
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.